Phase 1 topline: Onco3R Therapeutics completed dosing of the first cohort (n=6) in its first-in-human study of O3R-5671 with no clinically significant safety findings at 5 mg. Pharmacokinetic data supported dose escalation, and dosing of a higher second cohort is underway. A full readout is guided for the first half of 2026.
The core update is a controlled step forward for a selective SIK3 inhibitor aimed at inflammatory bowel disease and psoriasis. The Phase 1 study in healthy volunteers uses a single-ascending and multiple-ascending dose design with embedded pharmacodynamic biomarkers. In parallel, discovery and preclinical data on O3R-5671 were selected for a Late-Breaker oral presentation at United European Gastroenterology Week 2025 in Berlin, underscoring external interest ahead of patient studies planned to begin in 2026. Preclinical work suggests O3R-5671 suppresses TNFα, IL‑12, and IL‑23 while increasing IL‑10, and showed efficacy in animal models comparable to current standards of care.
Strategically, this is an entry into a crowded but still fluid immunology market where oral options with cleaner safety profiles are in demand. JAK inhibitors have efficacy but carry class warnings; TYK2 inhibitors are gaining ground in psoriasis and emerging in IBD; and IL‑23 biologics dominate moderate-to-severe disease. Onco3R’s bet is that a highly selective SIK3 mechanism can deliver broad anti‑inflammatory control without the liabilities linked to SIK1/2 or off‑target kinase effects. The biomarker-rich healthy volunteer approach is designed to de-risk dose selection and mechanism confirmation before committing to expensive mucosal healing or PASI-driven Phase 2 programs. The late-breaker slot helps frame the narrative, but clinical risk remains tied to whether human pharmacodynamics match the animal and in vitro signal.
For sites and CROs, the immediate activity sits with Phase 1 units and central labs capable of high-throughput cytokine and pathway assays, with operational emphasis on sample timing and assay reproducibility across SAD/MAD cohorts. If the program advances, GI and dermatology networks will need to integrate biomarker endpoints alongside standard clinical and endoscopic measures, which could add logistical complexity but may streamline dose optimization. Sponsors and competitors should note the renewed exploration of upstream oral immunomodulation in IBD after a period dominated by biologics and selective kinase agents; regulators will expect robust safety characterization, clear dose-response in pharmacodynamic markers, and disciplined transitions to patient endpoints such as endoscopic improvement and steroid-sparing.
What to watch next: evidence of target engagement in healthy volunteers, including consistent shifts in predefined cytokine panels across doses and clean multiple-dose tolerability. Any signal on food effect, QT, or CYP-mediated drug–drug interactions will influence Phase 2 protocol design and eligibility. The initial patient indication choice—ulcerative colitis versus Crohn’s or a dermatology lead—will set timelines and capital needs given differing endpoint complexity and duration. Competitive pressure from next-wave TYK2 programs in IBD and entrenched IL‑23 biologics will raise the bar on both efficacy and safety. Partnering and financing decisions in 2025–2026 will be a practical tell on how fast Onco3R can scale into multi-indication trials if the Phase 1 biomarkers and PK hold.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
